Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Sargent

Showing results (371-380 of 433) with videos related to

Pageof 44
Sort By:
Oncotarget|February 22, 2018
Consecutive epigenetically-active agent combinations act in <i>ID1-RUNX3-TET2</i> and <i>HOXA</i> pathways for <i>Flt3ITD+ve</i> AMLHamid Sayar, Yan Liu, Rui Gao, et al.
International Journal of Radiation Oncology, Biology, Physics|September 24, 2002
Impact of T and N substage on survival and disease relapse in adjuvant rectal cancer: a pooled analysisLeonard L Gunderson, Daniel J Sargent, Joel E Tepper, et al.
Bioorganic & Medicinal Chemistry Letters|April 8, 2010
Synthesis of 7-benzyl-5-(piperidin-1-yl)-6,7,8,9-tetrahydro-3H-pyrazolo[3,4-c][2,7]naphthyridin-1-ylamine and its analogs as bombesin receptor subtype-3 agonistsCheng Guo, Peter R Guzzo, Mark Hadden, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 28, 2002
Efficacy and quality-of-life data are related in a phase II trial of oral chemotherapy in previously untreated patients with metastatic colorectal carcinomaTimothy J Hobday, John W Kugler, Michelle R Mahoney, et al.
TAG. Theoretical and Applied Genetics. Theoretische Und Angewandte Genetik|July 5, 2018
Identification of powdery mildew resistance QTL in strawberry (Fragaria × ananassa)Helen M Cockerton, Robert J Vickerstaff, Amanda Karlström, et al.
Journal of the National Cancer Institute|January 2, 2017
Prognostic Value of BRAF and KRAS Mutations in MSI and MSS Stage III Colon CancerJulien Taieb, Karine Le Malicot, Qian Shi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 7, 2004
Pooled analysis of fluorouracil-based adjuvant therapy for stage II and III colon cancer: who benefits and by how much?Sharlene Gill, Charles L Loprinzi, Daniel J Sargent, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 16, 2014
Design of phase I combination trials: recommendations of the Clinical Trial Design Task Force of the NCI Investigational Drug Steering CommitteeChanning J Paller, Penelope A Bradbury, S Percy Ivy, et al.
The Lancet. Oncology|May 5, 2012
Phase 2 trial design in neuro-oncology revisited: a report from the RANO groupEvanthia Galanis, Wenting Wu, Timothy Cloughesy, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 26, 2010
Defective mismatch repair as a predictive marker for lack of efficacy of fluorouracil-based adjuvant therapy in colon cancerDaniel J Sargent, Silvia Marsoni, Genevieve Monges, et al.
Pageof 44

Showing results (371-380 of 433) with videos related to

Sort By:
Pageof 44
Oncotarget|February 22, 2018
Consecutive epigenetically-active agent combinations act in <i>ID1-RUNX3-TET2</i> and <i>HOXA</i> pathways for <i>Flt3ITD+ve</i> AMLHamid Sayar, Yan Liu, Rui Gao, et al.
International Journal of Radiation Oncology, Biology, Physics|September 24, 2002
Impact of T and N substage on survival and disease relapse in adjuvant rectal cancer: a pooled analysisLeonard L Gunderson, Daniel J Sargent, Joel E Tepper, et al.
Bioorganic & Medicinal Chemistry Letters|April 8, 2010
Synthesis of 7-benzyl-5-(piperidin-1-yl)-6,7,8,9-tetrahydro-3H-pyrazolo[3,4-c][2,7]naphthyridin-1-ylamine and its analogs as bombesin receptor subtype-3 agonistsCheng Guo, Peter R Guzzo, Mark Hadden, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 28, 2002
Efficacy and quality-of-life data are related in a phase II trial of oral chemotherapy in previously untreated patients with metastatic colorectal carcinomaTimothy J Hobday, John W Kugler, Michelle R Mahoney, et al.
TAG. Theoretical and Applied Genetics. Theoretische Und Angewandte Genetik|July 5, 2018
Identification of powdery mildew resistance QTL in strawberry (Fragaria × ananassa)Helen M Cockerton, Robert J Vickerstaff, Amanda Karlström, et al.
Journal of the National Cancer Institute|January 2, 2017
Prognostic Value of BRAF and KRAS Mutations in MSI and MSS Stage III Colon CancerJulien Taieb, Karine Le Malicot, Qian Shi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 7, 2004
Pooled analysis of fluorouracil-based adjuvant therapy for stage II and III colon cancer: who benefits and by how much?Sharlene Gill, Charles L Loprinzi, Daniel J Sargent, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 16, 2014
Design of phase I combination trials: recommendations of the Clinical Trial Design Task Force of the NCI Investigational Drug Steering CommitteeChanning J Paller, Penelope A Bradbury, S Percy Ivy, et al.
The Lancet. Oncology|May 5, 2012
Phase 2 trial design in neuro-oncology revisited: a report from the RANO groupEvanthia Galanis, Wenting Wu, Timothy Cloughesy, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 26, 2010
Defective mismatch repair as a predictive marker for lack of efficacy of fluorouracil-based adjuvant therapy in colon cancerDaniel J Sargent, Silvia Marsoni, Genevieve Monges, et al.
Pageof 44